Court decision: Stadler may deliver trains to SBB
After the decision, Stadler can start delivering the trains.
no. Stadler is allowed to deliver 268 trains for regional traffic to the SBB. This was decided by the Federal Administrative Court, as the SBB announced on Wednesday (May 25). The French competitor Alstom, who was inferior to Stadler in awarding the contract, had sued.
The order for up to 510 single-deck FLIRT multiple units went to Stadler last October. Clients were the SBB and its two subsidiaries Thurbo and RegionAlps. According to the announcement, the court has now confirmed that SBB complied with the procurement law requirements and the equal treatment of providers during the tendering process.
According to Stadler Rail, the order for 286 “FLIRT” trains with an order volume of around 2 billion francs is now planned for the first call. The framework contract includes the option of up to 224 additional trains. However, the procedure has delayed their commissioning: instead of the end of 2025, the trains will only be on the rails in the course of 2026.
Ypsomed has almost quadrupled its profit
The Ypsomed plant in Burgdorf (Canton Bern).
no. The medical technology company Ypsomed can look back on a successful 2021/22 financial year. Sales increased by 15 percent to 464.8 million Swiss francs, net profit increased almost fourfold from 5.8 million to 23.1 million Swiss francs. The operating result grew to 28.6 million Swiss francs compared to 9.3 million in the previous year.
Ypsomed thus just about met the expectations of the analysts. However, the estimates for operating and net profit were slightly higher. Nevertheless, the shareholders should be happy about the result: they will receive a dividend of CHF 0.60 per share.
The company is planning a capital increase to finance further growth. Specifically, it is about the issue of a maximum of one million fully paid up registered shares with a nominal value of CHF 14.15 each. It is planned to sell the unsubscribed shares as part of a free placement.
As in the previous year, Ypsomed is aiming for double-digit sales growth for the current financial year. In addition, the company expects a significant improvement in the operating result of at least 50 percent.